MEDI0382 Phase 2 trial to assess hepatic glycogen metabolism in overweight/obese T2DM patients

The global prevalence of Type 2 Diabetes Mellitus (T2DM) continues to rise, often co-occurring with obesity and Non-alcoholic fatty liver disease (NAFLD). NAFLD is increasingly recognized as the hepatic manifestation of metabolic syndrome, contributing significantly to liver disease worldwide. Current T2DM treatments often fall short in comprehensively addressing the complex interplay between glucose metabolism, lipid dysregulation, and hepatic health. Understanding how novel compounds like MEDI0382 impact hepatic glycogen metabolism is crucial for developing therapies that can mitigate these interconnected metabolic complications.

This Phase 2 clinical study, structured in two parts (A and B), is designed to evaluate the impact of MEDI0382 on hepatic glycogen metabolism. The trial will enroll approximately 20 subjects in Part A and an additional 30 subjects in Part B, totaling around 50 participants. The study population consists of overweight and obese individuals diagnosed with Type 2 Diabetes Mellitus. The primary endpoint is to investigate the characteristics of glucose and lipid metabolism, as well as fat distribution. Specific dosing, route of administration, frequency, and duration for MEDI0382 are not detailed in the provided abstract.